<DOC>
	<DOCNO>NCT02747927</DOCNO>
	<brief_summary>The purpose study evaluate efficacy 2 dos Tetravalent Dengue Vaccine Candidate ( TDV ) prevent symptomatic dengue fever severity due four dengue virus serotypes 4 16 year old participant .</brief_summary>
	<brief_title>Efficacy , Safety Immunogenicity Takeda 's Tetravalent Dengue Vaccine ( TDV ) Healthy Children</brief_title>
	<detailed_description>The vaccine test study Takeda 's Tetravalent Dengue Vaccine Candidate ( TDV ) . TDV test protect people dengue fever look long-term safety result . This study look success rate TDV prevent dengue fever ( vaccine efficacy ) long-term side effect vaccine . The study conduct 3 part . Part 1 evaluate vaccine efficacy ( VE ) last minimum 15 month . Part 2 additional 6 month evaluate VE . Part 3 evaluate long-term safety follow participant side effect last additional 3 year . Participants may enrol dry-run commence test febrile surveillance methodology ; dry-run part may upto 10 month prior receive study injection , however , applicable trial sit participant . Approximately 20,100 participant enrol study randomly assign ( chance ) one two treatment groups—which remain undisclosed participant study doctor study ( unless urgent medical need ) : - TDV 0.5 mL subcutaneous injection - Placebo ( dummy inactive subcutaneous injection ) - solution look like study drug active ingredient All participant receive single injection Day 1 Day 90 . A subset participant ask record local symptom injection site ( Pain , Erythema Swelling ) diary card 7 day injection . The subset participant also ask record systemic symptom ( child &lt; 6 year : fever , irritability/fussiness , drowsiness , loss appetite child ≥6 year : fever , headache , asthenia , malaise myalgia ) diary card 14 day injection . This multi-center trial conduct worldwide . The overall time participate study approximately 4.75 year exclude dry-run . Participants make multiple visit clinic contact least every week entire study duration .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Is age 4 16 year , inclusive , time randomization . 2 . Is good health time entry trial determine medical history , physical examination ( include vital sign ) clinical judgment Investigator . 3 . The participant and/or participant 's parent/guardian sign date assent/written informed consent form applicable , required privacy authorization prior initiation trial procedure , nature trial explain accord local regulatory requirement . 4 . Can comply trial procedure available duration followup . 1 . Has febrile illness ( temperature ≥38°C ) moderate severe acute illness infection time randomization . 2 . Has history illness , opinion Investigator , might interfere result trial pose additional risk participant due participation trial . 3 . Has receive vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior Day 1 ( Month 0 ) planning receive vaccine within 28 day Day 1 ( Month 0 ) . 4 . Has participate clinical trial another investigational product 30 day prior Day 1 ( Month 0 ) intent participate another clinical trial time conduct trial . 5 . Has previously participate clinical trial dengue candidate vaccine , previous receipt dengue vaccine . 6 . Is first degree relative individual involve trial conduct . 7 . Females childbearing potential sexually active , use acceptable contraceptive method least 2 month prior Day 1 ( Month 0 ) . 8 . Females childbearing potential sexually active , refuse use acceptable contraceptive method 6 week postsecond vaccination . 9 . Deprived freedom administrative court order , emergency setting , hospitalize involuntarily . 10 . Current alcohol abuse drug addiction may interfere participant 's ability comply trial procedure . 11 . Identified employee Investigator trial center , direct involvement propose trial trial direction Investigator trial center .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>